Bernhard Lmmle

List of Publications by Year in Descending Order

274 papers	14,662 citations	54 h-index	116 g-index
282 ext. papers	16,378 ext. citations	6 avg, IF	6.3 L-index

#	Paper	IF	Citations
274	Definite diagnosis of plasma prekallikrein deficiency should not be based exclusively on shortening of the aPTT upon prolonged pre-incubation.. *International Journal of Laboratory Hematology*, **2022**,	2.5	0
273	Redefining outcomes in immune TTP: an international working group consensus report. *Blood*, **2021** , 137, 1855-1861	2.2	28
272	Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. *Blood*, **2021**, 137, 3563-3575	2.2	10
271	c.451dupT in KLKB1 is common in Nigerians, confirming a higher prevalence of severe prekallikrein deficiency in Africans compared to Europeans. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 147-152	15.4	4
270	Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 478-488	15.4	6
269	Endothelial Dysfunction, Atherosclerosis, and Increase of Von Willebrand Factor and Factor VIII: A Randomized Controlled Trial in Swine. *Thrombosis and Haemostasis*, **2021**, 121, 552	7	
268	Influence of Personality, Resilience and Life Conditions on Depression and Anxiety in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
267	Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. *Journal of Clinical Medicine*, **2021**, 10,	5.1	23
266	No Evidence for Classic Thrombotic Microangiopathy in COVID-19. *Journal of Clinical Medicine*, **2021** , 10,	5.1	7
265	Diagnosis of Hereditary TTP Caused by Homozygosity for a Rare Complex ADAMTS13 Allele After Salmonella Infection in a 43-Year-Old Asylum Seeker. *Frontiers in Medicine*, **2021**, 8, 639441	4.9	0
264	Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura. *EJHaem*, **2021**, 2, 188-195	0.9	0
263	Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research. *Thrombosis Research*, **2021**, 204, 141-142	8.2	
262	Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura. *Blood Advances*, **2021**, 5, 3427-3435	7.8	6
261	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. *Blood*, **2020**, 136, 353-361	2.2	24
260	Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 1598-1617	15.4	10
259	ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients. *Thrombosis Research*, **2020**, 192, 174-175	8.2	42
258	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 732-739	15.4	32

257	Stealth thrombosis of brain and kidney in a girl with Upshaw-Schulman syndrome not receiving prophylactic plasma infusions. *International Journal of Hematology*, **2020**, 112, 603-604	2.3	2
256	Clinical Problem Solving and Using New Paths in the Laboratory: Learning from Case Studies. *Hamostaseologie*, **2020**, 40, 414-419	1.9	1
255	The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomized placebo-controlled superiority trial. *Scientific Reports*, **2020**, 10, 14219	4.9	5
254	Severe COVID-19 infection associated with endothelial activation. *Thrombosis Research*, **2020**, 190, 62	8.2	272
253	Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis. *Thrombosis and Haemostasis*, **2020**, 120, 538-564	7	39
252	Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: Pathophysiology and Differentiation from Graft versus Host Disease. *Thrombosis and Haemostasis*, **2019**, 119, 1382	7	0
251	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. *Haematologica*, **2019**, 104, 2107-2115	6.6	52
250	Risk stratification of elderly patients with acute pulmonary embolism. *European Journal of Clinical Investigation*, **2019**, 49, e13154	4.6	2
249	Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome. *Blood Advances*, **2019**, 3, 3191-3195	7.8	11
248	Standardized Management Protocol in Severe Postpartum Hemorrhage: A Single-Center Study. *Clinical and Applied Thrombosis/Hemostasis*, **2018**, 24, 884-893	3.3	2
247	Predictors and Outcomes of Recurrent Venous Thromboembolism in Elderly Patients. *American Journal of Medicine*, **2018**, 131, 703.e7-703.e16	2.4	10
246	Circulating extracellular DNA is an independent predictor of mortality in elderly patients with venous thromboembolism. *PLoS ONE*, **2018**, 13, e0191150	3.7	25
245	Hemophagocytic Lymphohistiocytosis in Early Infancy- Pitfall of Differentiation between Hereditary and Infectious Reasons. *Blood*, **2018**, 132, 4961-4961	2.2	1
244	Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature. *Blood*, **2018**, 132, 2496-2496	2.2	
243	Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients. *Blood*, **2018**, 132, 376-376	2.2	
242	Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab. *Thrombosis and Haemostasis*, **2018**, 118, 1743-1751	7	16
241	Opana ER-induced thrombotic microangiopathy. *Blood*, **2017**, 129, 808-809	2.2	3
240	Do Factor V Leiden and Prothrombin G20210A Mutations Predict Recurrent Venous Thromboembolism in Older Patients?. *American Journal of Medicine*, **2017**, 130, 1220.e17-1220.e22	2.4	5

239	Gut microbiota regulate hepatic von Willebrand factor synthesis and arterial thrombus formation via Toll-like receptor-2. *Blood*, **2017**, 130, 542-553	2.2	70
238	Depression and cognitive deficits as long-term consequences of thrombotic thrombocytopenic purpura. *Transfusion*, **2017**, 57, 1152-1162	2.9	26
237	Thrombotic thrombocytopenic purpura. *Nature Reviews Disease Primers*, **2017**, 3, 17020	51.1	139
236	Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. *American Journal of Medicine*, **2017**, 130, 198-206	2.4	51
235	Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. *Journal of Thrombosis and Haemostasis*, **2017**, 15, 312-322	15.4	236
234	Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation. *Thrombosis and Haemostasis*, **2017**, 117,	7	9
233	May-Thurner syndrome: missed diagnosis and missed early treatment?. *Hamostaseologie*, **2017**, 37, 184-185	1.9	1
232	Thromboembolism in patients with congenital afibrinogenaemia. Long-term observational data and systematic review. *Thrombosis and Haemostasis*, **2016**, 116, 722-32	7	25
231	Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency. *International Journal of Hematology*, **2016**, 103, 283-91	2.3	15
230	Anticoagulation Management Practices and Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Clinical Research Study. *PLoS ONE*, **2016**, 11, e0148348	3.7	8
229	Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 685-94	15.4	10
228	Thrombotic microangiopathy: Caplacizumab accelerates resolution of acute acquired TTP. *Nature Reviews Nephrology*, **2016**, 12, 259-60	14.9	3
227	High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 73-82	15.4	32
226	ADAMTS13 gene variants and function in women with preeclampsia: a population- based nested case- control study from the HUNT Study. *Thrombosis Research*, **2015**, 136, 282-8	8.2	3
225	Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 732-42	15.4	81
224	Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. *Journal of General Internal Medicine*, **2015**, 30, 17-24	4	49
223	VWF and complement. *Blood*, **2015**, 125, 896-8	2.2	
222	Depressive symptoms as a novel risk factor for recurrent venous thromboembolism: a longitudinal observational study in patients referred for thrombophilia investigation. *PLoS ONE*, **2015**, 10, e0125858	3.7	9

221	Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. *Journal of NeuroVirology*, **2015**, 21, 694-701	3.9	18
220	Current insights into thrombotic microangiopathies: Thrombotic thrombocytopenic purpura and pregnancy. *Thrombosis Research*, **2015**, 135 Suppl 1, S30-3	8.2	24
219	Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. *PLoS ONE*, **2015**, 10, e0117614	3.7	2
218	Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. *Blood*, **2014**, 123, 1674-80	2.2	40
217	The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs. *Blood*, **2014**, 124, 3469-79	2.2	30
216	Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura. *Hamostaseologie*, **2014**, 34, 244-8	1.9	4
215	Bilateral periorbital ecchymoses. An often missed sign of amyloid purpura. *Hamostaseologie*, **2014**, 34, 249-52	1.9	15
214	The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. *Thrombosis and Haemostasis*, **2014**, 111, 1180-3	7	19
213	Pearls, guidelines & more. *Hamostaseologie*, **2014**, 34, 199-199	1.9	
212	Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene. *European Journal of Haematology*, **2014**, 92, 168-71	3.8	8
211	In vitro rescue of FGA deletion by lentiviral transduction of an afibrinogenemic patient's hepatocytes. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 1874-9	15.4	3
210	Design and establishment of a biobank in a multicenter prospective cohort study of elderly patients with venous thromboembolism (SWITCO65+). *Journal of Thrombosis and Thrombolysis*, **2013**, 36, 484-91	5.1	8
209	The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. *Journal of Thrombosis and Thrombolysis*, **2013**, 36, 475-83	5.1	50
208	Plasma DNA is Elevated in Patients with Deep Vein Thrombosis. *Journal of Vascular Surgery: Venous and Lymphatic Disorders*, **2013**, 1,	3.2	75
207	Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry. *Hamostaseologie*, **2013**, 33, 138-43	1.9	33
206	Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. *Blood*, **2013**, 122, 2023-9; quiz 2142	2.2	112
205	Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. *Transfusion*, **2012**, 52, 2525-32; quiz 2524	2.9	49
204	Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. *American Journal of Hematology*, **2012**, 87, 430-2	7.1	59

203	Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer. *Presse Medicale*, **2012**, 41, e177-88	2.2	30
202	Prospective comparison of clinical prognostic scores in elder patients with a pulmonary embolism. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 2270-6	15.4	22
201	Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. *Blood*, **2012**, 120, 1157-64	2.2	198
200	Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. *Haematologica*, **2012**, 97, 89-97	6.6	43
199	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. *Haematologica*, **2012**, 97, 297-303	6.6	53
198	Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 610-6	3.1	15
197	Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. *Hematology American Society of Hematology Education Program*, **2012**, 2012, 610-616	3.1	50
196	Severe Depression Following Recovery From Thrombotic Thrombocytopenic Purpura (TTP). *Blood*, **2012**, 120, 366-366	2.2	2
195	International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) Upshaw-Schulman Syndrome. *Blood*, **2012**, 120, 4654-4654	2.2	1
194	Mortality and Morbidities During Long-Term Follow-up After Recovery From Thrombotic Thrombocytopenic Purpura (TTP). *Blood*, **2012**, 120, 362-362	2.2	1
193	Massive muscle haematoma three months after starting vitamin K antagonist therapy for deep-vein thrombosis in an antithrombin deficient patient: another case of factor IX propeptide mutation. *Thrombosis and Haemostasis*, **2011**, 106, 381-2	7	3
192	von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. *Blood*, **2011**, 117, 1400-7	2.2	294
191	On the dosing of lepirudin. *British Journal of Clinical Pharmacology*, **2011**, 72, 717	3.8	
190	Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. *Transfusion*, **2011**, 51, 2237-43	2.9	21
189	The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 140-8	15.4	19
188	Screening for lupus anticoagulant: improving the performance of the lupus-sensitive PTT-LA. *International Journal of Laboratory Hematology*, **2011**, 33, 168-75	2.5	2
187	Inhibitory Spleen-Derived Anti-ADAMTS13 Antibodies Are Characterized by a Limited Number of Variable Heavy Chain CDR3 Signatures in Patients with Relapsing Acquired Thrombotic Thromobocytopenic Purpura. *Blood*, **2011**, 118, 194-194	2.2	1
186	Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients. *Swiss Medical Weekly*, **2011**, 141, w13213	3.1	9

185	Long-Term Outcomes of Renal Function in Patients with TTP Associated with Severe ADAMTS13 Deficiency. *Blood*, **2011**, 118, 2215-2215	2.2	
184	Rumpel-Leede sign in thrombocytopenia due to Epstein-Barr virus-induced mononucleosis. *British Journal of Haematology*, **2010**, 148, 2	4.5	10
183	D-dimers predict stroke subtype when assessed early. *Cerebrovascular Diseases*, **2010**, 29, 82-6	3.2	52
182	Survival and relapse in patients with thrombotic thrombocytopenic purpura. *Blood*, **2010**, 115, 1500-11; quiz 1662	2.2	377
181	Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. *American Journal of Hematology*, **2010**, 85, 844-7	7.1	61
180	A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP). *Blood*, **2010**, 116, 726-726	2.2	4
179	Effective therapy with tranexamic acid in a case of chronic disseminated intravascular coagulation with acquired alpha2-antiplasmin deficiency associated with AL amyloidosis. *Thrombosis and Haemostasis*, **2009**, 102, 1285-7	7	4
178	Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. *Clinical Infectious Diseases*, **2009**, 48, 1129-37	11.6	38
177	Concomitant treatment with lamivudine renders cladribine inactive by inhibition of its phosphorylation. *British Journal of Haematology*, **2009**, 144, 136-7	4.5	7
176	Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. *Transfusion*, **2009**, 49, 873-87	2.9	83
175	Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. *Transfusion*, **2009**, 49, 1092-101	2.9	53
174	Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1649-55	15.4	25
173	Variability of anti-PF4/heparin antibody results obtained by the rapid testing system ID-H/PF4-PaGIA: reply to a rebuttal. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1755-1756	15.4	1
172	Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. *Blood*, **2009**, 113, 2402-9	2.2	34
171	Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. *British Journal of Haematology*, **2008**, 141, 696-707	4.5	47
170	The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection. *European Journal of Haematology*, **2008**, 80, 277-86	3.8	38
169	Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. *Thrombosis and Haemostasis*, **2008**, 99, 416-26	7	70
168	A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13. *Annals of Hematology*, **2008**, 87, 663-6	3	22

167	Characterization of Five Homozygous ADAMTS13 Mutations in Hereditary Thrombotic Thrombocytopenic Purpura Towards a Phenotype-Genotype Correlation?. *Blood*, **2008**, 112, 274-274	2.2	5
166	Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. *Haematologica*, **2007**, 92, 95-100	6.6	259
165	Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis. *Thrombosis and Haemostasis*, **2007**, 98, 1200-7	7	27
164	Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 866-7	15.4	58
163	ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 2284-90	15.4	135
162	Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. *Haematologica*, **2007**, 92, 936-43	6.6	60
161	Factor XIII in severe sepsis and septic shock. *Thrombosis Research*, **2007**, 119, 311-8	8.2	20
160	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. *Blood*, **2007**, 110, 1311-1311	2.2	3
159	The ADAMTS13 Gene as the Immunological Culprit in Acute Acquired TTP - First Evidence of Genetic Out-Breeding Depression in Humans.. *Blood*, **2007**, 110, 277-277	2.2	4
158	Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS.. *Blood*, **2007**, 110, 1317-1317	2.2	1
157	Beta2-Glycoprotein I: Implications for a Regulatory Role in Thrombotic Thrombocytopenic Purpura.. *Blood*, **2007**, 110, 278-278	2.2	0
156	Role of Microparticles in Thrombin Generation in Patients at Risk for Atherothrombosis.. *Blood*, **2007**, 110, 1624-1624	2.2	
155	Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT).. *Blood*, **2007**, 110, 1302-1302	2.2	
154	Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. *Swiss Medical Weekly*, **2007**, 137, 518-24	3.1	18
153	Hemophilia A pseudoaneurysm in a patient with high responding inhibitors complicating total knee arthroplasty: embolization: a cost-reducing alternative to medical therapy. *CardioVascular and Interventional Radiology*, **2006**, 29, 1132-5	2.7	17
152	ADAMTS13 activity in sickle cell disease. *American Journal of Hematology*, **2006**, 81, 492-8	7.1	44
151	A common origin of the 4143insA ADAMTS13 mutation. *Thrombosis and Haemostasis*, **2006**, 96, 3-6	7	64
150	Treatment of thrombotic thrombocytopenic purpura. *Vox Sanguinis*, **2006**, 90, 245-54	3.1	51

149	Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 1146-8	15.4	77
148	A new tool to further explore the role of ADAMTS-13 in health and disease. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 952-4	15.4	2
147	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP).. *Blood*, **2006**, 108, 1067-1067	2.2	2
146	Predicting Risk for Relapse in Patients Who Have Recovered from Thrombotic Thrombocytopenic Purpura (TTP).. *Blood*, **2006**, 108, 91-91	2.2	2
145	Pancreatitis Preceding Acute Episodes of Thrombotic Thrombocytopenic Purpura: Report of Five Patients with a Systematic Review of Published Reports.. *Blood*, **2006**, 108, 1058-1058	2.2	
144	Absolute and Relative Blood Lymphocyte Subset Counts before and during Treatment of Patients with Thrombotic Thrombocytopenic Purpura (TTP).. *Blood*, **2006**, 108, 3953-3953	2.2	
143	Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. *Blood*, **2005**, 105, 542-4	2.2	135
142	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. *Blood*, **2005**, 106, 1262-7	2.2	229
141	Usefulness of the D-dimer/fibrinogen ratio to predict deep venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 385-7	15.4	16
140	Thrombotic thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 1663-75	15.4	138
139	More on: thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 1549	15.4	1
138	The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 1432-6	15.4	247
137	Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS13 deficiency?. *Thrombosis and Haemostasis*, **2005**, 94, 1186-1189	7	12
136	Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. *Thrombosis and Haemostasis*, **2004**, 91, 276-82	7	44
135	Thrombotic thrombocytopenic purpura. *The Hematology Journal*, **2004**, 5 Suppl 3, S6-11		4
134	Potential role of d-dimer to rule in pulmonary embolism: reply to a rebuttal. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 369-370	15.4	1
133	von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. *Seminars in Hematology*, **2004**, 41, 75-82	4	69
132	Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. *Seminars in Hematology*, **2004**, 41, 48-59	4	35

131	Thrombotic thrombocytopenic purpura: advances in pathophysiology, diagnosis, and treatment--introduction. *Seminars in Hematology*, **2004**, 41, 1-3	4	11
130	Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. *Blood*, **2004**, 103, 4195-7	2.2	52
129	Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. *Blood*, **2004**, 103, 4514-9	2.2	178
128	Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities.. *Blood*, **2004**, 104, 856-856	2.2	2
127	The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency.. *Blood*, **2004**, 104, 857-857	2.2	2
126	Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes.. *Blood*, **2004**, 104, 858-858	2.2	1
125	Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults Following a Prodrome of Bloody Diarrhea.. *Blood*, **2004**, 104, 859-859	2.2	
124	Factor V Leiden Is Not a Risk Factor for Thrombotic Microangiopathies without Severe ADAMTS13 Deficiency.. *Blood*, **2004**, 104, 850-850	2.2	
123	ADAMTS13 Activity in Sickle Cell Disease: A Role in the Development of Clinical Vaso-Occlusion?.. *Blood*, **2004**, 104, 3738-3738	2.2	
122	Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. *Haematologica*, **2004**, 89, 320-4	6.6	40
121	The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **2003**, 33, 417-21		16
120	. *Blood Coagulation and Fibrinolysis*, **2003**, 14, 313	1	
119	ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. *Blood*, **2003**, 102, 60-8	2.2	552
118	Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. *Blood*, **2003**, 102, 1148	2.2	2
117	Hemostatic risk factors in ischemic stroke. *Thrombosis and Haemostasis*, **2003**, 90, 1094-9	7	9
116	Accuracy of D-dimer/fibrinogen ratio to predict pulmonary embolism: a prospective diagnostic study. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 708-13	15.4	65
115	Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 2042-2044	15.4	
114	Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. *Journal of Thrombosis and Haemostasis*, **2003**, 1, 1882-7	15.4	84

113	ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. *British Journal of Haematology*, **2003**, 120, 821-4	4.5	79
112	Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. *American Journal of Medicine*, **2003**, 114, 528-36	2.4	56
111	Elevated nucleosome levels in systemic inflammation and sepsis. *Critical Care Medicine*, **2003**, 31, 1947-51	1.4	677
110	Reply to Rebuttal: von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome. *Thrombosis and Haemostasis*, **2002**, 87, 549-550	7	2
109	Assays of von Willebrand factor-cleaving protease: a test for diagnosis of familial and acquired thrombotic thrombocytopenic purpura. *Seminars in Thrombosis and Hemostasis*, **2002**, 28, 167-72	5.3	22
108	C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. *Critical Care Medicine*, **2002**, 30, 1722-8	1.4	615
107	Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. *Blood*, **2002**, 100, 710-3	2.2	302
106	Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). *Blood*, **2002**, 100, 3626-32	2.2	197
105	Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. *Atherosclerosis*, **2002**, 161, 261-7	3.1	50
104	Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. *Thrombosis Research*, **2002**, 105, 441-6	8.2	48
103	Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. *Thrombosis Research*, **2002**, 105, 463-70	8.2	54
102	Platelets: thrombotic thrombocytopenic purpura. *Hematology American Society of Hematology Education Program*, **2002**, 315-34	3.1	48
101	Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. *Swiss Medical Weekly*, **2002**, 132, 443-8	3.1	27
100	Partial amino acid sequence of purified von Willebrand factor-cleaving protease. *Blood*, **2001**, 98, 1654-61	11.2	333
99	Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. *British Journal of Haematology*, **2001**, 113, 100-2	4.5	60
98	Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. *British Journal of Haematology*, **2001**, 113, 649-51	4.5	80
97	Protein Z in ischaemic stroke. *British Journal of Haematology*, **2001**, 114, 169-73	4.5	46
96	Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. *Rheumatology*, **2001**, 40, 940-2	3.9	19

95	Protein C replacement in severe meningococcemia: rationale and clinical experience. *Clinical Infectious Diseases*, **2001**, 32, 1338-46	11.6	62
94	Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. *Best Practice and Research in Clinical Haematology*, **2001**, 14, 437-54	4.2	187
93	Increased fibrin monomer plasma concentration in stable coronary artery disease in patients without oral anticoagulation. *Atherosclerosis*, **2001**, 157, 417-22	3.1	3
92	Frequency of protein Z deficiency in patients with ischaemic stroke. *Lancet, The*, **2001**, 358, 840-1	40	11
91	Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10). *Thrombosis and Haemostasis*, **2001**, 85, 454-457	7	19
90	Von Willebrand Factor-cleaving Protease in Childhood Diarrhoea-associated Haemolytic Uraemic Syndrome. *Thrombosis and Haemostasis*, **2001**, 85, 975-978	7	59
89	Hemostatic and fibrinolytic parameters in survivors of myocardial infarction: a low plasma level of plasmin-alpha2-antiplasmin complex is an independent predictor of coronary re-events. *Blood Coagulation and Fibrinolysis*, **2001**, 12, 17-24	1	12
88	Rapid D-dimer testing and pre-test clinical probability in the exclusion of deep venous thrombosis in symptomatic outpatients. *Blood Coagulation and Fibrinolysis*, **2001**, 12, 165-70	1	32
87	Splenectomy in thrombotic thrombocytopenic purpura. *American Journal of Hematology*, **2000**, 64, 79	7.1	1
86	Mycobacterium genavense infection in a patient with long-standing chronic lymphocytic leukaemia. *Journal of Internal Medicine*, **2000**, 248, 343-8	10.8	31
85	High Molecular Weight Kininogen Is Cleaved by FXIa at Three Sites: Arg409-Arg410, Lys502-Thr503 and Lys325-Lys326. *Thrombosis and Haemostasis*, **2000**, 83, 709-714	7	13
84	Agreement of D-dimer Results Measured by a Rapid ELISA (VIDAS) before and after Storage during 24 h or Transportation of the Original Whole Blood Samples. *Thrombosis and Haemostasis*, **2000**, 83, 177-178	7	12
83	Assay of von Willebrand Factor (vWF)-cleaving Protease Based on Decreased Collagen Binding Affinity of Degraded vWF. *Thrombosis and Haemostasis*, **1999**, 82, 1386-1389	7	277
82	Recovery and Half-Life of von Willebrand Factor-Cleaving Protease after Plasma Therapy in Patients with Thrombotic Thrombocytopenic Purpura. *Thrombosis and Haemostasis*, **1999**, 81, 8-13	7	161
81	Performance of a New Fibrin Monomer Assay to Exclude Deep Vein Thrombosis in Symptomatic Outpatients. *Thrombosis and Haemostasis*, **1999**, 81, 50-53	7	15
80	Von Willebrand Factor in Thrombotic Thrombocytopenic Purpura. *Thrombosis and Haemostasis*, **1999**, 82, 592-600	7	25
79	Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 1020-5	9.4	84
78	Fatal fresh frozen plasma infusion containing HPA-1a alloantibodies. *British Journal of Haematology* , **1999**, 106, 258-9	4.5	7

77	IFNalpha treatment in systemic mastocytosis. *Annals of Hematology*, **1999**, 78, 483-4	3	23
76	New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: case report and review. *European Journal of Pediatrics*, **1999**, 158, 883-7	4.1	23
75	Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. *Lancet, The*, **1999**, 353, 351-4	40	184
74	Fibrinogen Milano XIII (Aalpha 19 Arg-->Gly): a dysfunctional variant with an amino acid substitution in the N-terminal polymerization site. *Thrombosis Research*, **1999**, 96, 399-405	8.2	5
73	Fibrinogens Bern IV, Bern V and Milano XI. *Blood Coagulation and Fibrinolysis*, **1999**, 10, 93-100	1	10
72	Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. *Best Practice and Research: Clinical Haematology*, **1998**, 11, 509-14		36
71	Protein Z in healthy human individuals and in patients with a bleeding tendency. *British Journal of Haematology*, **1998**, 102, 1219-23	4.5	32
70	von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. *New England Journal of Medicine*, **1998**, 339, 1578-84	59.2	1449
69	Images in clinical medicine. Capnocytophaga canimorsus sepsis. *New England Journal of Medicine*, **1998**, 339, 1827	59.2	10
68	SimpliRED D-dimer Assay: Comparability of Capillary and Citrated Venous Whole Blood, Between-assay Variability, and Performance of the Test for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients. *Thrombosis and Haemostasis*, **1998**, 79, 1217-1219	7	34
67	Acquired Deficiency of von Willebrand Factor-Cleaving Protease in a Patient With Thrombotic Thrombocytopenic Purpura. *Blood*, **1998**, 91, 2839-2846	2.2	292
66	Influence of Low Molecular Weight Heparin and Low Molecular Weight Dextran Sulfate on the Inhibition of Coagulation Factor XIa by Serpins. *Thrombosis and Haemostasis*, **1998**, 80, 82-86	7	19
65	Venous thrombosis after caesarean section in a young woman with homozygous APC resistance and type I protein S deficiency. *European Journal of Haematology*, **1997**, 58, 127-9	3.8	4
64	Dural puncture and activated protein C resistance: risk factors for cerebral venous sinus thrombosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **1997**, 63, 351-6	5.5	56
63	Phenprocoumon-induced hepatitis delaying precise diagnosis in a thrombophilic patient with activated protein C resistance due to factor V R506Q mutation. *American Journal of Medicine*, **1997**, 103, 437-9	2.4	5
62	Deficient Activity of von Willebrand Factor□leaving Protease in Chronic Relapsing Thrombotic Thrombocytopenic Purpura. *Blood*, **1997**, 89, 3097-3103	2.2	470
61	Subcutaneous low-molecular-weight heparin for treatment of Trousseau□ syndrome. *Annals of Hematology*, **1997**, 75, 165-7	3	13
60	Plasma protein C inhibitor is elevated in survivors of myocardial infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 114-8	9.4	26

59	Activation of the Contact System in Patients With Sepsis and With Septic Shock. *Blood*, **1997**, 89, 3893-3794	7.2	224
58	Fibrinogen Claro--another dysfunctional fibrinogen variant with gamma 275 arginine-->histidine substitution. *Thrombosis Research*, **1996**, 81, 145-50	8.2	5
57	Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. *Blood*, **1996**, 87, 4223-4234	2.2	755
56	Binding of calcium ions and their effect on clotting of fibrinogen Milano III, a variant with truncated A alpha-chains. *Blood Coagulation and Fibrinolysis*, **1996**, 7, 331-5	1	5
55	Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. *Rheumatology*, **1996**, 35, 898-900	3.9	55
54	Biocompatibility in transfusion medicine. *Transfusion Science*, **1996**, 17, 481-488		5
53	Normal Binding of Calcium to Five Fibrinogen Variants with Mutations in the Carboxy Terminal Part of the Chain. *Thrombosis and Haemostasis*, **1996**, 76, 377-383	7	6
52	Plasminogen Deficiency: An Additional Risk Factor for Thrombosis in a Family with Factor V R506Q Mutation?. *Thrombosis and Haemostasis*, **1996**, 76, 475-476	7	7
51	The novel acceptor splice site mutation 11396(G-->A) in the factor XII gene causes a truncated transcript in cross-reacting material negative patients. *Human Molecular Genetics*, **1995**, 4, 1235-7	5.6	21
50	In vitro evaluation of the efficacy and biocompatibility of new, synthetic ABO immunoabsorbents. *Transplantation*, **1995**, 60, 425-30	1.8	28
49	No association of APC resistance with myocardial infarction. *Blood Coagulation and Fibrinolysis*, **1995**, 6, 456-9	1	31
48	Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites. *European Journal of Haematology*, **1994**, 53, 61-3	3.8	18
47	A new substitution, gamma 358 Ser-->Cys, in fibrinogen Milano VII causes defective fibrin polymerization. *Blood*, **1994**, 84, 1874-1880	2.2	20
46	Mucocutaneous bleeding, a rare but severe complication in nephrosialidosis. *European Journal of Pediatrics*, **1994**, 153, 703-4	4.1	1
45	Cold agglutinin syndrome and liver transplantation. *Vox Sanguinis*, **1994**, 67, 85	3.1	9
44	Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network. *Biochemical Journal*, **1994**, 298 (Pt 1), 157-63	3.8	26
43	Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353-->Pro leading to loss of a kallikrein cleavage site. *Blood*, **1994**, 84, 1173-1181	2.2	1
42	Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. *British Journal of Haematology*, **1993**, 85, 528-32	4.5	130

41	Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. *Proceedings of the National Academy of Sciences of the United States of America*, **1993**, 90, 7503-7	11.5	68
40	Fibrinogen Bern I: substitution gamma 337 Asn-->Lys is responsible for defective fibrin monomer polymerization. *Blood*, **1993**, 82, 2104-2108	2.2	9
39	Functional Characterization of a Variant Prekallikrein (PK Zürich). *Thrombosis and Haemostasis*, **1993**, 70, 427-432	7	9
38	Factor XII clotting activity and antigen levels in patients with thromboembolic disease. *Blood Coagulation and Fibrinolysis*, **1992**, 3, 555-61	1	28
37	Determination of thrombin-antithrombin-III-complex is not a suitable screening test for detecting deficiency of protein C or protein S. *Thrombosis Research*, **1992**, 66, 775-7	8.2	2
36	Functional Characterization of a Variant Factor XII (F XII Locarno) in a Cross Reacting Material Positive F XII Deficient Plasma. *Thrombosis and Haemostasis*, **1992**, 67, 219-225	7	7
35	Immunogold labelling of human von Willebrand factor adsorbed to collagen. *Blood Coagulation and Fibrinolysis*, **1991**, 2, 441-6	1	3
34	Major coagulation disorders when using aprotinin--observations on a case. *Thoracic and Cardiovascular Surgeon*, **1991**, 39, 196-8	1.6	6
33	Thromboembolism and Bleeding Tendency in Congenital Factor XII DeficienCy - A Study on 74 Subjects from 14 Swiss Families. *Thrombosis and Haemostasis*, **1991**, 65, 117-121	7	108
32	Purified Factor XII Has a Higher Specific Activity than the Parent Molecule in Plasma. *Thrombosis and Haemostasis*, **1991**, 65, 169-173	7	3
31	Inferior vena cava thrombosis in a child with nephroblastoma and combined deficiency of antithrombin III and free protein S. *Blut*, **1990**, 61, 295-7		4
30	Malondialdehyde formation by blood platelets: a diagnostic test to assess acetylsalicylic acid induced thrombocytopathy?. *Thrombosis Research*, **1990**, 59, 89-95	8.2	
29	A quantitative dot immunobinding assay for coagulation factor XII in plasma. *Journal of Immunological Methods*, **1990**, 130, 133-40	2.5	8
28	Decreased Free Protein S Levels in Polycythemia Vera. *Thrombosis and Haemostasis*, **1990**, 64, 177-178	7	6
27	Contact phase of blood coagulation is not activated in edema of high altitude. *Journal of Applied Physiology*, **1989**, 67, 1336-40	3.7	15
26	How high is the true fibrinogen content of fibrinogen standards?. *Thrombosis Research*, **1989**, 56, 583-92	8.2	16
25	Comments on "Quantification of human high molecular weight kininogen by immunoblotting with a monoclonal anti-light chain antibody" by Reddigari and Kaplan. *Journal of Immunological Methods*, **1989**, 125, 291-3	2.5	2
24	Purified Human Plasma Kallikrein Does Not Stimulate but Primes Neutrophils for Superoxide Production. *Thrombosis and Haemostasis*, **1989**, 62, 1121-1125	7	20

23	Virus-inactivated factor VIII concentrate prevents postoperative bleeding in a patient with von Willebrand's disease. *Transfusion*, **1988**, 28, 489-92	2.9	5
22	Tryptase from human mast cells does not activate purified human Hageman factor. *Clinical and Experimental Allergy*, **1988**, 18, 151-6	4.1	2
21	Heparin-dependent in vitro aggregation of normal platelets by plasma of a patient with heparin-induced skin necrosis: specific diagnostic test for a rare side effect. *American Journal of Medicine*, **1988**, 85, 721-4	2.4	29
20	Immunoblotting studies of the molecular forms of protein C in plasma. *Thrombosis Research*, **1988**, 52, 33-43	8.2	49
19	Haemorrhagic Shock Nine Days after Extracorporeal Shock Wave Lithotripsy in a Patient with Haemophilia B. *Thrombosis and Haemostasis*, **1988**, 60, 532	7	3
18	Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI. *Thrombosis and Haemostasis*, **1988**, 59, 151-161	7	26
17	Immunoblotting studies of coagulation factor XII, plasma prekallikrein, and high molecular weight kininogen. *Seminars in Thrombosis and Hemostasis*, **1987**, 13, 106-14	5.3	9
16	DETECTION AND QUANTITATION OF CLEAVED AND UNCLEAVED HIGH MOLECULAR WEIGHT KININOGEN IN PLASMA BY LIGAND BLOTTING WITH RADIOLABELED PLASMA PREKALLIKREIN OR FACTOR XI **1987**, 58, 0051		
15	AUTOACTIVATION OF HUMAN PLASMA PREKALLIKREIN **1987**, 58, 0099		1
14	Enhanced specificity of immunoblotting using radiolabeled antigen overlay: studies of blood coagulation factor XII and prekallikrein in plasma. *Analytical Biochemistry*, **1986**, 156, 118-25	3.1	20
13	Quantitative immunoblotting assay of blood coagulation factor XII. *Thrombosis Research*, **1986**, 41, 747-59	8.2	19
12	Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. *Blood*, **1986**, 68, 455-462	2.2	3
11	Heparin Cofactor II: Purification and Antibody Production. *Thrombosis and Haemostasis*, **1986**, 55, 019-023	7	8
10	Quantitative Immunoblotting of Plasma and Platelet Protein S. *Thrombosis and Haemostasis*, **1986**, 56, 382-386	7	9
9	Methodology and clinical significance of heparin cofactor II. Probable heparin cofactor II deficiency in a patient with cerebrovascular thrombosis. *Seminars in Thrombosis and Hemostasis*, **1985**, 11, 342-6	5.3	5
8	Treatment with stanozolol before thrombolysis in patients with arterial occlusions. *Thrombosis Research*, **1985**, 37, 529-32	8.2	6
7	Cold Promoted Activation and Factor XII, Prekallikrein and C1-Inhibitor. *Thrombosis and Haemostasis*, **1985**, 53, 242-244	7	8
6	Plasma prekallikrein, factor XII, antithrombin III, C1(-)-inhibitor and alpha 2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). *American Journal of Clinical Pathology*, **1984**, 82, 396-404	1.9	52

5	Factor VIII (procoagulant activity VIII:C, and antigen VIII:CAg, related antigen VIIIR:Ag and ristocetin cofactor VIIIR:Cof) in intensive care patients with clinically suspected disseminated intravascular coagulation (DIC). *American Journal of Clinical Pathology*, **1984**, 82, 565-72	1.9	9
4	Prekallikrein Activator - Reply. *Thrombosis and Haemostasis*, **1984**, 52, 366-366	7	
3	Assay of Factor XII clotting activity in heparinized plasma. *American Journal of Clinical Pathology*, **1983**, 80, 474-7	1.9	2
2	The Amidolytic Prekallikrein (PK) Determination: Enhanced PK Activation After Deep-Freezing of PatientsPPlasmas. *Thrombosis and Haemostasis*, **1983**, 49, 249-249	7	1
1	Monitoring of heparin treatment. Comparison of thrombin time, activated partial thromboplastin time, and plasma heparin concentration, and analysis of the behavior of antithrombin III. *American Journal of Clinical Pathology*, **1980**, 74, 68-73	1.9	34